Skip to main content
Erschienen in: Acta Diabetologica 2/2016

16.05.2015 | Original Article

GCKR polymorphism influences liver fat content in patients with type 2 diabetes

Erschienen in: Acta Diabetologica | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Aims

It has recently been shown that an allele in the glucokinase regulatory protein (GCKR) gene was associated with increased liver fat content in obese children. In this study, we set out to determine whether GCKR rs1260326 polymorphism was associated with liver fat content in patients with type 2 diabetes.

Methods

Three hundred and eight patients with type 2 diabetes were included in this study. Liver fat content was evaluated using 1H-MR spectroscopy.

Results

In our population, carriers of the rs1260326 minor T allele had a higher liver fat content than did carriers of the C allele homozygote (12.4 ± 9.6 vs. 10.3 ± 9.1 %, p = 0.03). The number of patients with steatosis was significantly higher in minor T allele carriers than in C allele homozygote carriers (70.7 vs. 55.4 %; p = 0.008). In multivariate analysis, the predictive variables for steatosis were BMI [odds ratio (OR) 1.08; 95 % confidence interval (CI) 1.03–1.13; p = 0.002], statin therapy (yes) [OR 0.54; 95 % CI 0.31–0.94; p = 0.03], metformin therapy (yes) [OR 2.67; 95 % CI 1.50–4.75; p < 0.001], and rs1260326 GCKR polymorphism (TT+CT) [OR 1.99; 95 % CI 1.14–3.47; p = 0.01].

Conclusions

This study shows that in patients with type 2 diabetes who were not selected for liver abnormalities, liver fat content was related to GCKR rs1260326 polymorphism independent of BMI, triglyceride levels, and age.
Literatur
1.
Zurück zum Zitat Cusi K (2009) Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16:141–149CrossRefPubMed Cusi K (2009) Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16:141–149CrossRefPubMed
2.
Zurück zum Zitat Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218CrossRefPubMed Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218CrossRefPubMed
3.
Zurück zum Zitat Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R et al (2008) Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31:165–169CrossRefPubMed Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R et al (2008) Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31:165–169CrossRefPubMed
4.
Zurück zum Zitat Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V et al (2009) Non-alcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 94:4103–4106CrossRefPubMed Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V et al (2009) Non-alcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 94:4103–4106CrossRefPubMed
5.
Zurück zum Zitat Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465CrossRefPubMedPubMedCentral Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P et al (2010) Specifically-PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 95:E430–E436CrossRefPubMed Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P et al (2010) Specifically-PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 95:E430–E436CrossRefPubMed
7.
Zurück zum Zitat Speliotes EK, Yerges-Armstrong L, Wu J, Hernaez R, Kim L, Palmer C, Gudnason V et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324CrossRefPubMedPubMedCentral Speliotes EK, Yerges-Armstrong L, Wu J, Hernaez R, Kim L, Palmer C, Gudnason V et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R et al (2012) Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55:781–789CrossRefPubMedPubMedCentral Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R et al (2012) Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55:781–789CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Petta S, Miele L, Bugianesi E, Cammà C, Rosso C, Boccia S et al (2014) Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 9:e87523CrossRefPubMedPubMedCentral Petta S, Miele L, Bugianesi E, Cammà C, Rosso C, Boccia S et al (2014) Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 9:e87523CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Rees MG, Wincovitch S, Schultz J, Waterstradt R, Beer NL, Baltrusch S et al (2012) Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55:114–122CrossRefPubMedPubMedCentral Rees MG, Wincovitch S, Schultz J, Waterstradt R, Beer NL, Baltrusch S et al (2012) Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55:114–122CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121CrossRefPubMedPubMedCentral Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Guiu B, Petit JM, Loffroy R, Ben Salem D, Aho S, Masson D et al (2009) Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 250:95–102CrossRefPubMed Guiu B, Petit JM, Loffroy R, Ben Salem D, Aho S, Masson D et al (2009) Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 250:95–102CrossRefPubMed
13.
Zurück zum Zitat Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387–1395CrossRefPubMed Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387–1395CrossRefPubMed
14.
Zurück zum Zitat Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S et al (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462–E468CrossRefPubMed Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S et al (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462–E468CrossRefPubMed
15.
Zurück zum Zitat Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T et al (2010) Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105:1567–1573CrossRefPubMedPubMedCentral Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T et al (2010) Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105:1567–1573CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M (1999) Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22:756–761CrossRefPubMed de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M (1999) Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22:756–761CrossRefPubMed
17.
Zurück zum Zitat Lynedjian PB (2009) Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 66:27–42CrossRef Lynedjian PB (2009) Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 66:27–42CrossRef
18.
Zurück zum Zitat Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M et al (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18:4081–4088CrossRefPubMedPubMedCentral Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M et al (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18:4081–4088CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Sparsø T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70–75CrossRefPubMed Sparsø T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70–75CrossRefPubMed
20.
Zurück zum Zitat Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116CrossRefPubMedPubMedCentral Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Königsrainer A et al (2011) Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96:E1126–E1130CrossRefPubMed Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Königsrainer A et al (2011) Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96:E1126–E1130CrossRefPubMed
22.
Zurück zum Zitat Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC et al (2011) Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34:1139–1144CrossRefPubMedPubMedCentral Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC et al (2011) Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34:1139–1144CrossRefPubMedPubMedCentral
Metadaten
Titel
GCKR polymorphism influences liver fat content in patients with type 2 diabetes
Publikationsdatum
16.05.2015
Erschienen in
Acta Diabetologica / Ausgabe 2/2016
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-015-0766-4

Weitere Artikel der Ausgabe 2/2016

Acta Diabetologica 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.